Bahir Chamseddin is a Dermatology physician affiliated with The University of Texas Southwestern Medical Center. OpenAlex indexes 25 publications with 635 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202530 payments
- Galderma Laboratories, L.P.Program year202516 payments
- Janssen Biotech, Inc.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
33.8%Azole Antifungal33.8%Ketoconazole100%Part D<11 patientsSensory organs
26.5%Corticosteroid26.5%Clobetasol Propionate100%Part D<11 patientsCardiovascular
20.6%Arteriolar Vasodilator20.6%Minoxidil100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway
Lupus Science & Medicine
2025 - LB1132 Portable tools to quantify stiffness as an outcome measure for cutaneous neurofibroma in NF1
Journal of Investigative Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Toto, MD
The University of Texas Southwestern Medical Center
Abhimanyu Garg, MD
The University of Texas Southwestern Medical Center
Graham Emslie, MD
The University of Texas Southwestern Medical Center
Jing Chen, MD
The University of Texas Southwestern Medical Center
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”